Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3050)
All Articles published online
|
Dec 28, 2007 (publication date) through Apr 20, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Schmitz K, Lang H, Wohlschlaeger J, Sotiropoulos G, Reis H, Schmid K, Baba H. AKT and ERK1/2 signaling in intrahepatic cholangiocarcinoma. World J Gastroenterol 2007; 13(48): 6470-6477 [PMID: 18161916 DOI: 10.3748/wjg.v13.i48.6470] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v13/i48/6470.htm |
| Number | Citing Articles |
| 1 |
Shanshan Zhang, Xinhua Song, Dan Cao, Zhong Xu, Biao Fan, Li Che, Junjie Hu, Bin Chen, Mingjie Dong, Maria G. Pilo, Antonio Cigliano, Katja Evert, Silvia Ribback, Frank Dombrowski, Rosa M. Pascale, Antonio Cossu, Gianpaolo Vidili, Alberto Porcu, Maria M. Simile, Giovanni M. Pes, Gianluigi Giannelli, John Gordan, Lixin Wei, Matthias Evert, Wenming Cong, Diego F. Calvisi, Xin Chen. Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice. Journal of Hepatology 2017; 67(6): 1194 doi: 10.1016/j.jhep.2017.07.006
|
| 2 |
Alexandre Dos Santos, Magali Court, Valérie Thiers, Sokhavuth Sar, Catherine Guettier, Didier Samuel, Christian Bréchot, Jérôme Garin, France Demaugre, Christophe D. Masselon. Identification of Cellular Targets in Human Intrahepatic Cholangiocarcinoma Using Laser Microdissection and Accurate Mass and Time Tag Proteomics. Molecular & Cellular Proteomics 2010; 9(9): 1991 doi: 10.1074/mcp.M110.000026
|
| 3 |
DUSP1 inhibits cell proliferation, metastasis and invasion and angiogenesis in gallbladder cancer. Oncotarget 2017; 8(7): 12133 doi: 10.18632/oncotarget.14815
|
| 4 |
Mark Yarchoan, Leslie Cope, Amanda N. Ruggieri, Robert A. Anders, Anne M. Noonan, Laura W. Goff, Lipika Goyal, Jill Lacy, Daneng Li, Anuj K. Patel, Aiwu R. He, Ghassan K. Abou-Alfa, Kristen Spencer, Edward J. Kim, S. Lindsey Davis, Autumn J. McRee, Paul R. Kunk, Subir Goyal, Yuan Liu, Lauren Dennison, Stephanie Xavier, Aditya A. Mohan, Qingfeng Zhu, Andrea Wang-Gillam, Andrew Poklepovic, Helen X. Chen, Elad Sharon, Gregory B. Lesinski, Nilofer S. Azad. Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers. Journal of Clinical Investigation 2021; 131(24) doi: 10.1172/JCI152670
|
| 5 |
Angela Dalia Ricci, Alessandro Rizzo, Chiara Bonucci, Nastassja Tober, Andrea Palloni, Veronica Mollica, Ilaria Maggio, Marzia Deserti, Simona Tavolari, Giovanni Brandi. PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?. Medicines 2020; 7(9): 54 doi: 10.3390/medicines7090054
|
| 6 |
Pei Tiemin, Meng Fanzheng, Xiao Peng, Han Jihua, Song Ruipeng, Lan Yaliang, Wang Yan, Xue Junlin, Lang Qingfu, He Zhefeng, Li Jian, Guo Zihao, Liu Guoxing, Sun Boshi, Zhao Ming, Meng Qinghui, Liang Desen, Liu Lianxin. MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways. Journal of Hepatology 2020; 72(4): 761 doi: 10.1016/j.jhep.2019.11.021
|
| 7 |
Ina Nepstad, Kimberley Joanne Hatfield, Ida Sofie Grønningsæter, Håkon Reikvam. The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells. International Journal of Molecular Sciences 2020; 21(8): 2907 doi: 10.3390/ijms21082907
|
| 8 |
Shounan Lu, Shanjia Ke, Chaoqun Wang, Yanan Xu, Zihao Li, Keda Song, Miaoyu Bai, Menghua Zhou, Hongjun Yu, Bing Yin, Xinglong Li, Zhigang Feng, Yongliang Hua, Shangha Pan, Hongchi Jiang, Linqiang Li, Yaohua Wu, Yong Ma. NNMT Promotes Aerobic Glycolysis and Tumorigenesis by Upregulating EGFR Expression in Cholangiocarcinoma. SSRN Electronic Journal 2021; doi: 10.2139/ssrn.3981540
|
| 9 |
Imeshi Wijetunga, Laura E. McVeigh, Antonia Charalambous, Agne Antanaviciute, Ian M. Carr, Amit Nair, K. Raj Prasad, Nicola Ingram, P. Louise Coletta. Translating Biomarkers of Cholangiocarcinoma for Theranosis: A Systematic Review. Cancers 2020; 12(10): 2817 doi: 10.3390/cancers12102817
|
| 10 |
Jingxiao Wang, Haichuan Wang, Michele Peters, Ning Ding, Silvia Ribback, Kirsten Utpatel, Antonio Cigliano, Frank Dombrowski, Meng Xu, Xinyan Chen, Xinhua Song, Li Che, Matthias Evert, Antonio Cossu, John Gordan, Yong Zeng, Xin Chen, Diego F. Calvisi. Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis. Journal of Hepatology 2019; 71(4): 742 doi: 10.1016/j.jhep.2019.05.027
|
| 11 |
WEI YANG, XIAOYUAN WANG, WEI ZHENG, KEDONG LI, HAOFENG LIU, YUEMING SUN. Genetic and epigenetic alterations are involved in the regulation of TPM1 in cholangiocarcinoma. International Journal of Oncology 2013; 42(2): 690 doi: 10.3892/ijo.2012.1741
|
| 12 |
Dakeun Lee, In-Gu Do, Kyusam Choi, Chang Ohk Sung, Kee-Taek Jang, Dongwook Choi, Jin Seok Heo, Seoung Ho Choi, Jongmin Kim, Jin Young Park, Hyung Jin Cha, Jae-Won Joh, Kwan Yong Choi, Dae Shick Kim. The expression of phospho-AKT1 and phospho-MTOR is associated with a favorable prognosis independent of PTEN expression in intrahepatic cholangiocarcinomas. Modern Pathology 2012; 25(1): 131 doi: 10.1038/modpathol.2011.133
|
| 13 |
Paweena Dana, Kulthida Vaeteewoottacharn, Ryusho Kariya, Kouki Matsuda, Sopit Wongkham, Seiji Okada. Repurposing cimetidine for cholangiocarcinoma: Antitumor effects in vitro and in vivo. Oncology Letters 2017; 13(3): 1432 doi: 10.3892/ol.2017.5563
|
| 14 |
Sara Huber, Theresia Fitzner, René G. Feichtinger, Sarah Hochmann, Theo Kraus, Karl Sotlar, Barbara Kofler, Martin Varga. Galanin System in the Human Bile Duct and Perihilar Cholangiocarcinoma. Cells 2023; 12(13): 1678 doi: 10.3390/cells12131678
|
| 15 |
Jae-Sun Choi, Mi Suk Lee, Joo-Won Jeong. Ethyl pyruvate has a neuroprotective effect through activation of extracellular signal-regulated kinase in Parkinson’s disease model. Biochemical and Biophysical Research Communications 2010; 394(3): 854 doi: 10.1016/j.bbrc.2010.03.105
|
| 16 |
Jaume Capdevila, Francisco Javier Ramos, Teresa Macarulla, Elena Elez, Manuel Ruiz-Echarri, Jose Perez-Garcia, Josep Tabernero. Development of new drug strategies in infrequent digestive tumors: esophageal, biliary tract, and anal cancers. Current Opinion in Oncology 2009; 21(4): 374 doi: 10.1097/CCO.0b013e32832c9464
|
| 17 |
Daniel H. Ahn, Tanios Bekaii-Saab. Textbook of Gastrointestinal Oncology. 2019; : 185 doi: 10.1007/978-3-030-18890-0_11
|
| 18 |
Francesca Corti, Federico Nichetti, Alessandra Raimondi, Monica Niger, Natalie Prinzi, Martina Torchio, Elena Tamborini, Federica Perrone, Giancarlo Pruneri, Maria Di Bartolomeo, Filippo de Braud, Sara Pusceddu. Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives. Cancer Treatment Reviews 2019; 72: 45 doi: 10.1016/j.ctrv.2018.11.001
|
| 19 |
Mickaël Di‐Luoffo, Sophie Pirenne, Thoueiba Saandi, Axelle Loriot, Claude Gérard, Nicolas Dauguet, Fátima Manzano‐Núñez, Natália Alves Souza Carvalhais, Florence Lamoline, Sabine Cordi, Katarzyna Konobrocka, Vitaline De Greef, Mina Komuta, Georg Halder, Patrick Jacquemin, Frédéric P. Lemaigre. A Mouse Model of Cholangiocarcinoma Uncovers a Role for Tensin‐4 in Tumor Progression. Hepatology 2021; 74(3): 1445 doi: 10.1002/hep.31834
|
| 20 |
Daniel Walden, Selvi Kunnimalaiyaan, Kevin Sokolowski, T. Clark Gamblin, Muthusamy Kunnimalaiyaan. Antiproliferative and apoptotic effects of xanthohumol in cholangiocarcinoma. Oncotarget 2017; 8(50): 88069 doi: 10.18632/oncotarget.21422
|
| 21 |
Shi-Jun Yue, Peng-Xuan Zhang, Yue Zhu, Nian-Guang Li, Yan-Yan Chen, Jia-Jia Li, Sai Zhang, Ru-Yi Jin, Hao Yan, Xu-Qin Shi, Yu-Ping Tang, Jin-Ao Duan. A Ferulic Acid Derivative FXS-3 Inhibits Proliferation and Metastasis of Human Lung Cancer A549 Cells via Positive JNK Signaling Pathway and Negative ERK/p38, AKT/mTOR and MEK/ERK Signaling Pathways. Molecules 2019; 24(11): 2165 doi: 10.3390/molecules24112165
|
| 22 |
Hsing-Ju Wu, Pei-Yi Chu. Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications. International Journal of Molecular Sciences 2019; 20(17): 4154 doi: 10.3390/ijms20174154
|
| 23 |
Hyuk Moon, Hyunjung Park, Min Jee Chae, Hye Jin Choi, Do Young Kim, Simon Weonsang Ro. Activated TAZ induces liver cancer in collaboration with EGFR/HER2 signaling pathways. BMC Cancer 2022; 22(1) doi: 10.1186/s12885-022-09516-1
|
| 24 |
Kais Zakharia, Katsuyuki Miyabe, Yu Wang, Dehai Wu, Catherine D. Moser, Mitesh J. Borad, Lewis R. Roberts. Preclinical In Vitro and In Vivo Evidence of an Antitumor Effect of CX-4945, a Casein Kinase II Inhibitor, in Cholangiocarcinoma. Translational Oncology 2019; 12(1): 143 doi: 10.1016/j.tranon.2018.09.005
|
| 25 |
Piyasiri Chueakwon, Peeranat Jatooratthawichot, Krajang Talabnin, James R. Ketudat Cairns, Chutima Talabnin. Inhibition of Ceramide Glycosylation Enhances Cisplatin Sensitivity in Cholangiocarcinoma by Limiting the Activation of the ERK Signaling Pathway. Life 2022; 12(3): 351 doi: 10.3390/life12030351
|
| 26 |
Anna Xie, Jingjing Wang, Yi Liu, Guoqing Li, Nanyang Yang. Impacts of β-1, 3-N-acetylglucosaminyltransferases (B3GNTs) in human diseases. Molecular Biology Reports 2024; 51(1) doi: 10.1007/s11033-024-09405-9
|
| 27 |
Sun Lixin, Sun Wei, Song Haibin, Lang Qingfu, Pei Tiemin. miR‐885‐5p inhibits proliferation and metastasis by targeting IGF2BP1 and GALNT3 in human intrahepatic cholangiocarcinoma. Molecular Carcinogenesis 2020; 59(12): 1371 doi: 10.1002/mc.23262
|
| 28 |
DONGSHENG XU, YONG MA, BAOLEI ZHAO, SHUAI LI, YU ZHANG, SHANGHA PAN, YAOHUA WU, JIZHOU WANG, DAWEI WANG, HUAYANG PAN, LIANXIN LIU, HONGCHI JIANG. Thymoquinone induces G2/M arrest, inactivates PI3K/Akt and nuclear factor-κB pathways in human cholangiocarcinomas both in vitro and in vivo. Oncology Reports 2014; 31(5): 2063 doi: 10.3892/or.2014.3059
|
| 29 |
Xianqiong Liu, Junjie Hu, Xinhua Song, Kirsten Utpatel, Yi Zhang, Pan Wang, Xinjun Lu, Jie Zhang, Meng Xu, Tao Su, Li Che, Jingxiao Wang, Matthias Evert, Diego Calvisi, Xin Chen. Combined Treatment with MEK and mTOR Inhibitors is Effective in In Vitro and In Vivo Models of Hepatocellular Carcinoma. Cancers 2019; 11(7): 930 doi: 10.3390/cancers11070930
|
| 30 |
Anna Saborowski, Michael Saborowski, Monika A. Davare, Brian J. Druker, David S. Klimstra, Scott W. Lowe. Mouse model of intrahepatic cholangiocarcinoma validates FIG–ROS as a potent fusion oncogene and therapeutic target. Proceedings of the National Academy of Sciences 2013; 110(48): 19513 doi: 10.1073/pnas.1311707110
|
| 31 |
Yang Zou, Rong Li, Dabin Kuang, Meiling Zuo, Wenqun Li, Wei Tong, Li Jiang, Min Zhou, Yin Chen, Wencheng Gong, Lijuan Liu, Fangfang Tou. Galangin Inhibits Cholangiocarcinoma Cell Growth and Metastasis through Downregulation of MicroRNA-21 Expression. BioMed Research International 2020; 2020: 1 doi: 10.1155/2020/5846938
|
| 32 |
Shounan Lu, Shanjia Ke, Chaoqun Wang, Yanan Xu, Zihao Li, Keda Song, Miaoyu Bai, Menghua Zhou, Hongjun Yu, Bing Yin, Xinglong Li, Zhigang Feng, Yongliang Hua, Shangha Pan, Hongchi Jiang, Linqiang Li, Yaohua Wu, Yong Ma. NNMT promotes the progression of intrahepatic cholangiocarcinoma by regulating aerobic glycolysis via the EGFR-STAT3 axis. Oncogenesis 2022; 11(1) doi: 10.1038/s41389-022-00415-5
|
| 33 |
Rachna T Shroff, Mark Yarchoan, Ashley O'Connor, Denise Gallagher, Marianna L Zahurak, Gary Rosner, Chimela Ohaji, Susan Sartorius-Mergenthaler, Vivek Subbiah, Ralph Zinner, Nilofer S Azad. The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma. British Journal of Cancer 2017; 116(11): 1402 doi: 10.1038/bjc.2017.119
|
| 34 |
Supawan Jamnongsong, Patipark Kueanjinda, Pongsakorn Buraphat, Phuwanat Sakornsakolpat, Kulthida Vaeteewoottacharn, Seiji Okada, Siwanon Jirawatnotai, Somponnat Sampattavanich. Comprehensive Library of Drug Response and Pan-Omic Analysis Identified Therapeutic Candidates and Accompanying Prognostic Biomarkers for Asian Cholangiocarcinoma. SSRN Electronic Journal 2022; doi: 10.2139/ssrn.4131651
|
| 35 |
Malinee Thanee, Hasaya Dokduang, Yingpinyapat Kittirat, Jutarop Phetcharaburanin, Poramate Klanrit, Attapol Titapun, Nisana Namwat, Narong Khuntikeo, Arporn Wangwiwatsin, Hideyuki Saya, Watcharin Loilome, Salvatore V Pizzo. CD44 modulates metabolic pathways and altered ROS-mediated Akt signal promoting cholangiocarcinoma progression. PLOS ONE 2021; 16(3): e0245871 doi: 10.1371/journal.pone.0245871
|
| 36 |
Michael Höpfner, Detlef Schuppan, Hans Scherübl. Targeted medical therapy of biliary tract cancer: Recent advances and future perspectives. World Journal of Gastroenterology 2008; 14(46): 7021-7032 doi: 10.3748/wjg.14.7021
|
| 37 |
Supawan Jamnongsong, Patipark Kueanjinda, Pongsakorn Buraphat, Phuwanat Sakornsakolpat, Kulthida Vaeteewoottacharn, Seiji Okada, Siwanon Jirawatnotai, Somponnat Sampattavanich. Comprehensive drug response profiling and pan-omic analysis identified therapeutic candidates and prognostic biomarkers for Asian cholangiocarcinoma. iScience 2022; 25(10): 105182 doi: 10.1016/j.isci.2022.105182
|